Leerink Partnrs Brokers Decrease Earnings Estimates for KYTX

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of Kyverna Therapeutics in a report released on Wednesday, November 12th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.66) per share for the year, down from their prior forecast of ($3.63). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.82) EPS, FY2026 earnings at ($3.27) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($3.97) EPS and FY2029 earnings at ($3.26) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.12.

Several other equities analysts have also recently commented on the stock. Wells Fargo & Company lifted their target price on shares of Kyverna Therapeutics from $27.00 to $31.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. HC Wainwright increased their price target on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday. Finally, William Blair started coverage on Kyverna Therapeutics in a research note on Wednesday, August 20th. They issued an “outperform” rating for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Kyverna Therapeutics Stock Performance

Kyverna Therapeutics stock opened at $7.83 on Monday. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $8.45. The firm’s 50-day simple moving average is $6.35 and its 200 day simple moving average is $4.32. The stock has a market cap of $342.95 million, a PE ratio of -2.10 and a beta of 3.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KYTX. Jacobs Levy Equity Management Inc. purchased a new stake in Kyverna Therapeutics in the 3rd quarter worth about $886,000. Woodline Partners LP purchased a new stake in Kyverna Therapeutics during the third quarter valued at about $1,513,000. Qube Research & Technologies Ltd boosted its position in Kyverna Therapeutics by 161.1% during the third quarter. Qube Research & Technologies Ltd now owns 36,691 shares of the company’s stock worth $220,000 after purchasing an additional 22,640 shares during the period. Public Employees Retirement System of Ohio bought a new position in Kyverna Therapeutics during the third quarter worth about $28,000. Finally, Millennium Management LLC increased its stake in shares of Kyverna Therapeutics by 21.9% in the third quarter. Millennium Management LLC now owns 551,635 shares of the company’s stock worth $3,310,000 after purchasing an additional 99,075 shares in the last quarter. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.